Literature DB >> 15687222

Contribution of the ATP binding site of ParE to susceptibility to novobiocin and quinolones in Streptococcus pneumoniae.

Philippe Dupont1, Alexandra Aubry, Emmanuelle Cambau, Laurent Gutmann.   

Abstract

In Streptococcus pneumoniae, an H103Y substitution in the ATP binding site of the ParE subunit of topoisomerase IV was shown to confer quinolone resistance and hypersensitivity to novobiocin when associated with an S84F change in the A subunit of DNA gyrase. We reconstituted in vitro the wild-type topoisomerase IV and its ParE mutant. The ParE mutant enzyme showed a decreased activity for decatenation at subsaturating ATP levels and was more sensitive to inhibition by novobiocin but was as sensitive to quinolones. These results show that the ParE alteration H103Y alone is not responsible for quinolone resistance and agree with the assumption that it facilitates the open conformation of the ATP binding site that would lead to novobiocin hypersensitivity and to a higher requirement of ATP.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15687222      PMCID: PMC545609          DOI: 10.1128/JB.187.4.1536-1540.2005

Source DB:  PubMed          Journal:  J Bacteriol        ISSN: 0021-9193            Impact factor:   3.490


  32 in total

1.  Varying levels of positive and negative supercoiling differently affect the efficiency with which topoisomerase II catenates and decatenates DNA.

Authors:  J Roca
Journal:  J Mol Biol       Date:  2001-01-19       Impact factor: 5.469

2.  A model for the mechanism of strand passage by DNA gyrase.

Authors:  S C Kampranis; A D Bates; A Maxwell
Journal:  Proc Natl Acad Sci U S A       Date:  1999-07-20       Impact factor: 11.205

3.  Mutational analysis of Escherichia coli topoisomerase IV. II. ATPase negative mutants of parE induce hyper-DNA cleavage.

Authors:  P Nurse; S Bahng; E Mossessova; K J Marians
Journal:  J Biol Chem       Date:  2000-02-11       Impact factor: 5.157

4.  New mutation in parE in a pneumococcal in vitro mutant resistant to fluoroquinolones.

Authors:  C Janoir; E Varon; M D Kitzis; L Gutmann
Journal:  Antimicrob Agents Chemother       Date:  2001-03       Impact factor: 5.191

5.  Fluoroquinolones inhibit preferentially Streptococcus pneumoniae DNA topoisomerase IV than DNA gyrase native proteins.

Authors:  E Fernandez-Moreira; D Balas; I Gonzalez; A G de la Campa
Journal:  Microb Drug Resist       Date:  2000       Impact factor: 3.431

6.  Cleavable-complex formation by wild-type and quinolone-resistant Streptococcus pneumoniae type II topoisomerases mediated by gemifloxacin and other fluoroquinolones.

Authors:  Genoveva Yague; Julia E Morris; Xiao-Su Pan; Katherine A Gould; L Mark Fisher
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

7.  Grepafloxacin, a dimethyl derivative of ciprofloxacin, acts preferentially through gyrase in Streptococcus pneumoniae: role of the C-5 group in target specificity.

Authors:  Julia E Morris; Xiao-Su Pan; L Mark Fisher
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

8.  Probing the interaction of the cytotoxic bisdioxopiperazine ICRF-193 with the closed enzyme clamp of human topoisomerase IIalpha.

Authors:  S Patel; E Jazrawi; A M Creighton; C A Austin; L M Fisher
Journal:  Mol Pharmacol       Date:  2000-09       Impact factor: 4.436

9.  Genetic analyses of mutations contributing to fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae.

Authors:  L M Weigel; G J Anderson; R R Facklam; F C Tenover
Journal:  Antimicrob Agents Chemother       Date:  2001-12       Impact factor: 5.191

10.  Quinolone resistance mutations in Streptococcus pneumoniae GyrA and ParC proteins: mechanistic insights into quinolone action from enzymatic analysis, intracellular levels, and phenotypes of wild-type and mutant proteins.

Authors:  X S Pan; G Yague; L M Fisher
Journal:  Antimicrob Agents Chemother       Date:  2001-11       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.